Aesthetic Clinic Biologics Supplier Serving Syracuse, NY

What aesthetic practices ask for before purchasing

Medspas and aesthetic practices evaluating a biologics distributor typically start by requesting the certificate of analysis format and the donor eligibility summary, since these describe how tissue is screened and tested before it reaches a clinic. Some practices also ask how sterility testing is handled, which Precision Biologics addresses by pointing to the third-party lab testing and quarantine release process applied to every lot.

This review is usually completed by whoever already manages supplier relationships for injectables or topical products at the practice.

Physician supervision and NPI verification

Because many medspas operate under a supervising physician, Precision Biologics ties each account to a specific NPI and checks it against the NPPES registry before activating pricing access. Practices should set the account up under the NPI that matches their actual supervisory structure.

Confirming the supervising physician's licensure standing with the New York medical board, and reviewing how any product fits the practice's regulatory posture, remains the practice's own responsibility together with its counsel; Precision Biologics does not provide that review.

Shipping and storage for a Syracuse practice

Cryopreserved formats travel overnight on dry ice in validated containers and need prompt transfer to -80 degree C storage after arrival, so practices should schedule deliveries for days with staff coverage. Lyophilized Wharton's jelly and exosome formats are shelf-stable under normal storage and are reconstituted or handled according to the insert included with the lot.

How Precision Biologics supports new accounts

Once an NPI is verified, Precision Biologics releases the standard documentation set, including the certificate of analysis, donor eligibility summary, and lot release record, so a practice's internal review can proceed without an initial order. Practices tracking product by lot at the patient record level can request lot-specific documents as each shipment arrives.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.